Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Immuno-oncology company Neon Therapeutics raises $70mm in Series B financing; later adds $36mm more

Executive Summary

Neon Therapeutics raised $70mm in its Series B financing round led by Partner Fund Management. Returning backers Third Rock Ventures and Access Industries joined new investors Fidelity Management & Research, Wellington Management Company, Inbio Ventures, and Nextech Invest. The company will use the funds toward its lead program NEOPV01, a fully personalized neoantigen vaccine, currently in Phase Ib trials; for preclinical development of NEOPTC01, a personalized adoptive T-cell program; and for the Shared Neoantigen Program. Neon has raised $125mm to date through its A and B rounds.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies